How to Add HRT Services to an Existing Medical Practice

Share this article:

An established medical practice already has the hardest parts of a hormone therapy business: patients who trust you and clinicians who know them. What it usually lacks is the layer around the visit: prescribing workflow, pharmacy routing, lab ordering and monitoring, recurring-care billing, and compliance. A white-label telehealth platform lets you add that layer under your own brand in as little as seven days, subject to onboarding and approvals, instead of assembling vendors one at a time. 

This guide explains how to start an HRT clinic inside the practice you already run: how to choose between hiring, training, and partnering; how to pick a delivery model; a day-by-day launch checklist; compliance in plain language; the lab and monitoring workflow; the revenue model; and the 2026 FDA and DEA developments you need to know. 

The short answer 

• Most practices don’t lack patients or clinicians. They lack infrastructure: pharmacy routing, labs, monitoring, recurring care, and consent and compliance workflows. 

• You have three paths: hire an HRT provider, train your existing clinicians, or partner with a white-label platform. Many practices combine two. 

• On Homely MD, launch can take as little as seven days, subject to onboarding and approvals, with an accelerated path of as little as four hours for eligible businesses that have their assets and information ready. 

• Check current rules first: FDA has changed menopausal hormone therapy and testosterone labeling, and DEA telemedicine flexibilities run only through December 31, 2026.

What changed: FDA and DEA developments (as of November 6, 2026) 

Three regulatory threads shape how you design an HRT program right now. None of them is a green light for every patient, but each changes how you build consent, monitoring, and your telehealth model. 

Development What happened What it means for your practice
FDA menopausal hormone therapy labelsAfter a review that began in November 2025, FDA approved updated labeling for six products on February 12, 2026, and for three estradiol patches on October 30, 2026. Outdated statements on cardiovascular disease, breast cancer, and probable dementia were removed from their boxed warnings. Twenty-nine manufacturers have submitted proposed changes, so more may follow.Patients are asking more questions, and clinicians are revisiting protocols. As one PA quoted in Contemporary OB/GYN put it, removing a boxed warning “does not mean hormone therapy is appropriate for everyone.” Keep individualized risk assessment and informed consent at the center.
FDA testosterone labelsIn February 2025, FDA announced class-wide changes: results of the TRAVERSE trial were added, cardiovascular-risk language was removed from the boxed warning, and a blood pressure warning was added or expanded for all testosterone products. The limitation of use for age-related hypogonadism remains.Update consent forms and monitoring to address blood pressure, and keep indications and marketing aligned with labeled use and your clinicians’ judgment.
DEA telemedicine flexibilitiesThe fourth extension runs through December 31, 2026. It lets DEA-registered practitioners prescribe Schedule II-V controlled substances by telemedicine without a prior in-person evaluation, subject to conditions. DEA’s special registration rule, proposed in January 2025, is still not final.Testosterone is Schedule III, so telehealth TRT depends on these rules. Estrogen and progesterone are not controlled substances. Plan a hybrid option in case the rules change after December 31, 2026.
Compounded hormonesHHS’s October 30 release notes that 503A compounding remains available for individual patients with a valid prescription.Ask your pharmacy how it sources and labels compounded products, and never claim compounded or “bioidentical” products are safer or more effective than FDA-approved options.

Infrastructure first: what an HRT program actually needs 

Courses teach you the medicine, and EHR vendors sell you software. Neither gives you a working program on its own. A hormone therapy service runs on five building blocks, and a gap in any one stalls the launch.

Building block What it must do
Licensed prescribers Evaluate patients, set the treatment plan, and prescribe, with medical oversight that meets your state’s rules
Pharmacy routing Send patient-specific prescriptions to a licensed pharmacy, handle compounding where used, and ship direct to the patient, with cold-chain shipping where required
Lab workflow Order baseline and follow-up panels, return results into the patient’s chart, and trigger follow-up
Patient platform Intake, scheduling, charting, e-prescribing, patient portal, and video, audio, and chat
Compliance layer Consent, state licensing, controlled-substance rules, privacy, and advertising review

Homely MD is an all-in-one platform for healthcare providers that covers the first four layers under one contract and one invoice: the white-label platform, licensed clinicians, 24+ 503A compounding pharmacy partners, and integrated labs. Compliance is shared, and the matrix below shows who carries what. 

Hire, train, or partner? A side-by-side 

Hire an HRT provider Train your clinicians White-label partner
Time to first patientDepends on recruiting and credentialingDepends on training time, plus building the restAs little as 7 days, subject to onboarding and approvals
Upfront work Recruiting, credentialing, malpractice, protocolsTraining, protocols, and separate pharmacy, lab, and software vendorsOnboarding and branding
Clinician coverageThat provider’s licenses and scheduleYour clinicians’ licensed statesLicensed clinicians across all 50 states
Control Highest High You own the brand, patient relationships, and data. Clinical decisions stay with licensed clinicians.
Best when High volume and an in-house buildInterested clinicians and patients in your own stateYou want a fast, multi-state launch with no separate vendors

These options aren’t exclusive. Many practices train in-house clinicians to see in-person patients and use a partner for telehealth coverage and infrastructure.

Choose your delivery model: telehealth-only, in-person, or hybrid

Model Strengths Watch-outs
Telehealth-only Reach beyond your location, convenient for follow-ups, lower overheadPrescriber must be licensed where the patient is located. Telehealth testosterone depends on DEA flexibilities that run through Dec 31, 2026. No in-office procedures.
In-person Physical exams, in-office procedures such as pellet insertion, familiar to existing patientsLimited to your location and schedule, and your capacity
Hybrid Telehealth for follow-ups, refills, and lab reviews, with in-person visits for exams and procedures. Keeps an in-person path ready if DEA rules change.Needs a clear workflow for when each visit type is used

For an existing practice, hybrid is usually the most natural starting point: your current patients keep their familiar relationship with your clinicians, and telehealth extends your reach and convenience. 

The 7-day launch checklist for an existing practice 

What “7 days” means 

• Included: platform configuration, branding, intake and consent, provider and pharmacy workflow, lab ordering, and a tested soft launch. 

• Not guaranteed by the platform: attorney turnaround, malpractice carrier review, and payment-processor approval. Start those on Day 0. 

Day 0: Before the clock starts 

Decide what you are launching. 

  •  Pick the first offering: hormone therapy for menopause, testosterone therapy for men, or both. 
  •  Decide who you will offer it to first (existing patients are the fastest path) and in which states or locations. 
  •  Gather brand assets and onboarding documents, and book a health care attorney and a call with your malpractice carrier. 

Day 1: Choose your model and confirm oversight 

Decide who does what. 

  • Choose API integration with your existing website, or a complete white-label platform. Homely MD supports both. 
  •  Confirm with counsel how medical oversight, supervision, and prescribing authority work in your states.
  •  Confirm with your carrier that the new services are covered under your own policy. 

Your clinical leaders own this step. 

  •  Define indications, contraindications, and shared decision-making for each therapy. [ ] Write informed consent that reflects current labeling, including the updated menopausal hormone therapy labels and the testosterone blood pressure warning, plus any compounded status. 
  •  Decide who is authorized to prescribe what, and how controlled-substance prescribing is handled. 

Day 3: Pharmacy and labs 

Connect the supply chain. 

  •  Choose formulations and route prescriptions to the right pharmacy. For compounded products, confirm a licensed 503A pharmacy. 
  •  Confirm shipping, including cold chain where required, and direct-to-patient delivery. 
  • Map your lab panels and how results return to the chart.

Day 4: Configure the platform and your brand 

Make it feel like your practice. 

  •  Set up your portal, domain, intake, scheduling, e-prescribing, and video, audio, and chat. 
  • Set membership terms, refill rules, and refund and cancellation policy. [ ] Add consent screens, privacy notices, and clear disclosure of compounded status where it applies. 

Day 5: Claims review and patient communication 

Say it accurately. 

– Review website and email copy against the compliance rules below, and have counsel review it. 

–  Announce to existing patients, and give front-desk staff a short script and FAQ. 

– Keep ad tracking pixels off intake and logged-in pages. 

Day 6: Test the whole journey 

Find problems before patients do. 

– Run a test patient through intake, clinician review, e-prescription, pharmacy order, lab order and result, and delivery. 

– If you will prescribe testosterone, test the controlled-substance workflow, including your DEA registration and any state requirements such as prescription monitoring checks. 

– Test refills, lab reminders, and an adverse-event or complaint escalation.

Day 7: Soft launch and monitoring 

Start with patients who already know you. 

– Open to a first group of existing patients and track enrollment, time to first visit, and lab completion. 

– Assign one person to check FDA and DEA developments weekly, especially before December 31, 2026. 

– After week one, add states, new patient groups, and further service lines. Homely MD supports eight service lines with no additional per-service-line charge. 

Compliance in plain language: who carries what 

This is a typical allocation of responsibility. Your contract and state law decide the final answer, so confirm each row in writing. 

Responsibility Your practice Homely MD network and platformPharmacy and lab partners
Brand, patient relationships, and patient dataOwned by you Provides the infrastructure behind your brand–
Clinical decisions for patients seen by network clinicians– Licensed network clinicians decide–
Clinical decisions for your own patientsYour licensed clinicians – –
Malpractice coverage Your own policy for your own clinicians. Confirm with your carrier.Carried by Homely MD for its providers ($1M minimum per occurrence)–
Medical oversight Defined by state law and your agreement. Confirm with counsel.Defined by state law and your agreement–
Compounding quality and labelingChoose and audit your pharmacyPharmacy network Pharmacy
Lab processing and results– Results appear in the chart Lab partner
Marketing claims You – –

Six rules of thumb: 

• License follows the patient. Prescribers must be licensed where the patient is located at the time of the visit. 

• Medical oversight is set by state law. Requirements for medical directors and for supervising or collaborating physicians vary, so get the structure in writing.

• Consent must be current. Reflect today’s labeling, any compounded status, and the patient’s individual risk. 

• Controlled substances have extra rules. Testosterone is Schedule III. It requires DEA registration, state rules, and a plan for the telemedicine rules after December 31, 2026. • Advertising must be truthful. No “FDA-approved” for compounded products, no “safer” or “more natural” claims for compounded or “bioidentical” hormones, and clear disclosure of paid endorsements. 

• Protect privacy. Make sure a business associate agreement is in place, and review any ad tracking. 

Lab and monitoring workflow 

Monitoring is where an HRT program succeeds or fails, because it drives safety and retention. Your medical director sets the actual panels and schedule, and guidelines evolve. This table shows how to build the workflow. 

Phase What happens Typical categories (set by your clinicians)
Baseline Intake, history, exam, and baseline labs before the first prescriptionRelevant hormone levels, metabolic and lipid markers, blood count, thyroid, and liver. Blood pressure check.
Early follow-up Re-check after starting or changing a dose, and review symptoms and side effectsRepeat of the markers your clinician selects, plus blood pressure
Ongoing Scheduled reviews, refills, and lab reminders at your chosen cadenceMarkers per protocol, such as blood count for testosterone patients. Add PSA where clinically indicated.

Homely MD includes five ready-built lab panels (TRT, HRT, Comprehensive, Peptide, and BPC), covering up to 52 biomarkers, ordered and resulted in the same chart. Confirm which biomarkers each panel includes during onboarding. Many programs tie refill approvals to completed monitoring, at the clinician’s discretion, which keeps patients on schedule and protects safety. 

The revenue model: recurring care without the guesswork 

Hormone therapy is recurring care, not a one-time procedure. A typical program earns from a few connected streams. Pricing depends on your configuration and is provided by the Homely MD team, so this section covers structure only.

Revenue stream How it works
Membership or program fee Covers visits, messaging, and monitoring over a set period
Medication Prescriptions fulfilled through your pharmacy partners
Lab panels Baseline and follow-up panels ordered through the platform
Revenue stream How it works
Add-on services Other service lines you add later, with no additional per-service-line charge at Homely MD

Track the metrics that tell you whether the program is healthy: enrollment rate among eligible existing patients, time to first visit, lab completion rate, refill adherence, 90-day retention, and revenue per active patient. 

How to start an HRT clinic with a white-label HRT telehealth platform 

Homely MD is a technology-enabled care network for businesses and practices. It is a B2B service, so your brand stays out front while the clinical engine runs underneath, and you keep the patient relationships and data. As a telehealth platform for hormone therapy providers, it gives you a white label HRT telehealth program with one partner, one contract, and one invoice: 

• Platform: patient portal, dynamic intake, scheduling, charting, e-prescribing, and unlimited video, audio, and chat. 

• Providers: licensed, credentialed clinicians across all 50 states, with malpractice coverage carried by Homely MD. 

• Pharmacy: 24+ 503A compounding pharmacy partners, with patient-specific compounding and direct-to-patient delivery. 

• Labs: five ready-built panels, including HRT and TRT, ordered and resulted in the same chart. 

Whether you want an HRT telehealth platform behind your existing website through API integration, or a complete white-label build, you can start a telehealth business line inside your practice without hiring a provider, building the technology, or signing separate pharmacy and lab contracts. Confirm which therapies, formulations, and states are available at launch during onboarding. 

Ready to add hormone therapy to your practice? 

Talk to Homely MD about launching your branded hormone therapy telehealth platform in as little as seven days, subject to onboarding and approvals.

Frequently asked questions 

How do I add HRT services to an existing medical practice? 

Choose a model (hire, train, or partner), then set up five building blocks: licensed prescribers, pharmacy routing, a lab and monitoring workflow, a patient platform, and a compliance layer covering consent, state licensing, and controlled-substance rules. On a white-label telehealth platform such as Homely MD, an existing practice can launch hormone therapy under its own brand in as little as seven days, subject to onboarding and approvals. 

What is an HRT telehealth platform, and what should it include? 

An HRT telehealth platform is software plus clinical infrastructure for delivering hormone therapy remotely. At minimum it should include patient intake, scheduling, charting, e-prescribing, video or messaging, lab ordering with results in the chart, and pharmacy routing. Homely MD bundles these with licensed clinicians across all 50 states and 24+ 503A compounding pharmacy partners under one contract and one invoice. The customer owns the brand and patient data. 

Should I hire an HRT provider, train my staff, or use a white-label partner?

It depends on volume, speed, and geography. Hiring gives the most control but depends on recruiting and credentialing timelines. Training your clinicians works when they are licensed where your patients are, but you still need pharmacy, labs, and technology. A white-label partner supplies the infrastructure and multi-state clinician coverage quickly. Many practices combine them: train in-house clinicians for in-person patients and use a partner for telehealth. 

Can I prescribe testosterone by telehealth in 2026? 

As of November 6, 2026, DEA telemedicine flexibilities, extended through December 31, 2026, let DEA-registered practitioners prescribe Schedule II-V controlled substances by telemedicine without a prior in-person evaluation, subject to conditions. Testosterone is Schedule III. DEA’s special registration rule is still only proposed, and state laws still apply, so many practices keep an in-person option ready for 2027. 

What did FDA change on menopausal hormone therapy labels? 

FDA approved updated labeling for six menopausal hormone therapy products on February 12, 2026, and for three estradiol patches on October 30, 2026, removing outdated cardiovascular disease, breast cancer, and probable dementia statements from their boxed warnings. Twenty-nine manufacturers have submitted proposed changes, so more updates may follow. Removing a boxed warning does not make hormone therapy right for everyone, so individualized risk assessment and consent still apply.

Share this post:

Related Articles

Uncategorized

FDA’s Interim Access Policy for Peptides: What It Means for Your Telehealth Peptide Program

For the last three years, building a telehealth peptide program meant operating in a gray zone. Many of the most

TRT Telehealth

How to Choose the Best TRT Telehealth Provider: A Guide for Healthcare Businesses

Men’s health is becoming an increasingly important part of the digital healthcare market. As more patients look for convenient access

HRT Telehealth Platform

HRT Telehealth Platform: A Guide for Hormone Therapy Providers

Hormone therapy is one of the fastest-growing areas of virtual care. Patients want convenient, ongoing support, and med spas, wellness